Study of matrix metalloproteinases and their inhibitors in breast cancer.
about
Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: New findings and review of the literaturePhysical biology in cancer. 5. The rocky road of metastasis: the role of cytoskeletal mechanics in cell migratory response to 3D matrix topographyBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Integration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancerTumor-derived matrix metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer.Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitorsCirculating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease.HN1 contributes to migration, invasion, and tumorigenesis of breast cancer by enhancing MYC activity.Study of matrix metalloproteinases and their inhibitors in prostate cancer.Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.MMP-1 expression has an independent prognostic value in breast cancer.Quantitative analysis of the secretome of TGF-beta signaling-deficient mammary fibroblasts.MMP-1 is a (pre-)invasive factor in Barrett-associated esophageal adenocarcinomas and is associated with positive lymph node status.Raf-induced MMP9 disrupts tissue architecture of human breast cells in three-dimensional culture and is necessary for tumor growth in vivo.Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis.Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development.Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancerPlasma matrix metalloproteinase 1, 3, and 7 levels and breast cancer risk in the Nurses' Health study.Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells.Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancerCancer progression by breast tumors with Pit-1-overexpression is blocked by inhibition of metalloproteinase (MMP)-13.Mammary carcinoma with osteoclast-like giant cells: a case report.Matrix metalloproteinases and their inhibitors in canine mammary tumorssiRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells.Matrix metalloproteinases: protective roles in cancer.Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis.Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expressionPeptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.A phenotype from tumor stroma based on the expression of metalloproteases and their inhibitors, associated with prognosis in breast cancer.The Clinical Significance and Molecular Features of the Spatial Tumor Shapes in Breast CancersMatrix metalloproteinases as breast cancer drivers and therapeutic targets.Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.Matrix metalloprotease-1a promotes tumorigenesis and metastasis.Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinomaIntrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion.Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse.Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancerIntegrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancerTIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells
P2860
Q24652514-24DE7FA8-22F4-499F-AB6C-42842BCE304FQ27021875-AFCF2D32-A592-4881-B047-3EF62917E44DQ27311085-D171F157-FB6A-48BF-BB4B-3E9746947E86Q28538685-7A86F113-8DE8-4D89-89BC-7EEAB977446EQ33326151-5375B246-65FC-48AF-B33E-7895445FEBB2Q33338236-FCC658B4-D7A5-44ED-93E6-998FC28441B8Q33514944-DA063E74-60B7-4C3D-A114-B5B88438CB1EQ33660320-601CF62A-80C9-4082-8041-E0690C14AE66Q33708162-DA6884CC-3CD9-4D1A-A01F-2E08FE38FCECQ33757096-E99E1E04-688B-4B04-88EE-71FCA4624174Q33915005-F98BFE7B-F019-4478-A7F2-6244ED920DFFQ33991012-3FDD4E02-9EE1-473F-85B6-459AEE0DDB01Q34145178-2E653E36-627B-460C-B5DF-AB274A6F084CQ34258256-DA584803-C8D6-40F9-B755-ECBA17383E9FQ34411893-F500B781-6CA0-4BAB-AAFA-1FDFA44D42AAQ34457039-F2744934-C922-41B1-86EA-E8B2B88A8FC1Q34473935-E9216C58-30B1-4B0E-ADDD-F618C9648A16Q34541239-B79D51C3-C6EE-4FAB-9851-A0CB59D4EB79Q34543608-E61D0B64-BF14-4FB8-B6ED-14A3E8902519Q34786543-BF078899-2A37-4A0C-908C-8B7979D8FD04Q34995520-A1DCFB4F-8B74-4B57-8C38-69838CB10D67Q35008756-F6EF51F7-1FC2-4BCD-8F13-E7FD9F58308FQ35038508-D3970DCA-75D2-4C8A-9806-1246516CEE9AQ35121300-B50CCCCB-F1AF-4C1E-9AF3-63826F96FC93Q35207239-01EC0425-8348-44F5-AEE0-92D00CE5BB10Q35216059-8AB05965-D657-4F1C-8B26-1F8621B76742Q35310572-0146EF81-D2F8-4A8D-9C5D-A29A9AA7DB72Q35550160-7B196F99-C461-4486-B05B-F72EDACD14A0Q35783096-1ACF4C65-2DB2-4D8B-B054-FA9C79A2D124Q35798885-83EC66D1-A90C-4054-8BC6-B7B9A7460086Q35869105-3867517F-3077-407E-B2E7-5215D49EDA53Q35892721-BC860484-5135-4B92-BB32-00C05A813EFEQ36003640-14833FE5-4A47-477C-807E-EF2B21CC2A6FQ36097959-9EC9151B-E3FA-460E-BDA1-28EB9C2016ACQ36430125-B02C02D5-D3BE-42E4-B442-3F4A1F173D53Q36458763-368DB032-E3B4-422B-AE8F-91179E463FDBQ36611308-F115E97D-C029-401A-96B0-6634246D0670Q36678647-0635E538-DA27-406A-A8B4-3679DA14061EQ36747858-92D891E3-D0A8-4010-9784-7D974569AD3AQ36787339-407E2257-33F8-441D-AE3E-9690CC19320C
P2860
Study of matrix metalloproteinases and their inhibitors in breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@ast
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@en
type
label
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@ast
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@en
prefLabel
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@ast
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@en
P2093
P2860
P356
P1476
Study of matrix metalloproteinases and their inhibitors in breast cancer.
@en
P2093
A M Merino
F J Vizoso
J C Rodríguez
J L García-Muñiz
L O González
M L Lamelas
S Junquera
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603666
P407
P577
2007-03-06T00:00:00Z